Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation

References

• Vidal A, Koff A. Cell-cycle inhibitors: Three families united by a common cause. Gene. 2000;247:1–15
   PubMed Web of Science ®Google Scholar
• Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11:973–983
   PubMed Web of Science ®Google Scholar
• Wang S, Kim JH, Moon KC, Hong HK, Lee HS. Cell cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:19–27
   Google Scholar
• Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C. Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int. 2005;68:1109–1119
   Google Scholar
• Ding M, Cui S, Li C, Jothy S, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med. 2006;12:1081–1087
   PubMed Web of Science ®Google Scholar
• Thorner PS, Ho M, Eremina V, Sado Y, Quaggin S. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol. 2008;19:495–502
   PubMed Web of Science ®Google Scholar
• Smeets B, Uhlig S, Fuss A, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol. 2009;20:2604–2615
   PubMed Web of Science ®Google Scholar
• Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600–2610
   PubMed Web of Science ®Google Scholar
• Schnaper HW, Hayashida T, Poncelet AC. It’s a Smad world: Regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol. 2002;13:1126–1128
   PubMedGoogle Scholar
• Liu Y. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–217
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim BK, Moon KC, Hong HK, Lee HS. Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 2003;64:1715–1721
   PubMed Web of Science ®Google Scholar
• Kim TS, Kim JY, Hong HK, Lee HS. mRNA expression of glomerular basement membrane proteins and TGF-β1 in human membranous nephropathy. J Pathol. 1999;189:425–430
   PubMed Web of Science ®Google Scholar
• Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-b1 develop progressive renal disease. Lab Invest. 1996;74:991–1003
   PubMed Web of Science ®Google Scholar
• Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor b1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 1995;92:2572–2576
   PubMed Web of Science ®Google Scholar
• Shimizu M, Kondo S, Urushihara M, et al. Role of integrin-linked kinase in epithelial mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant. 2006;21:2380–2390
   Google Scholar
• Kim HW, Moon KC, Park SY, Hong HK, Lee HS. Differential expression of platelet-derived growth factor and transforming growth factor-b in relation to progression of IgA nephropathy. Nephrology. 2002;7:S131–S139
   Google Scholar
• Patek CE, Fleming S, Miles CG, et al. Murine Denys-Drash syndrome: Evidence of podocyte dedifferentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet. 2003;12:2379–2394
   Google Scholar
• Lee HS, Song CY. Effects of TGF-β on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res. 2010;33:24–29
   Google Scholar
• Franzen P, Ten Dijke P, Ichijo H, et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 1993;75:681–692
   PubMed Web of Science ®Google Scholar
• Massague J, Blain SW, Lo RS. TGF-β signalling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309
   PubMed Web of Science ®Google Scholar
• Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-bJreceptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16:5353–5362
   PubMed Web of Science ®Google Scholar
• Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1:611–617
   PubMed Web of Science ®Google Scholar
• Massague J, Wotton D. Transcriptional control by TGF-bJ/Smad signaling. EMBO J. 2000;19:1745–1754
   PubMed Web of Science ®Google Scholar
• Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, aTGFbeta-inducible antagonist of TGF-beta signalling. Nature. 1997;389:631–635
   PubMed Web of Science ®Google Scholar
• Shi Y, Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell. 2003;113:685–700
   PubMed Web of Science ®Google Scholar
• de Caestecker MP, Yahata T, Wang D, et al. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem. 2000;275:2115–2122
   PubMedGoogle Scholar
• Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with co-activator p300/CREBbinding protein. Mol Biol Cell. 1998;9:3309–3319
   PubMed Web of Science ®Google Scholar
• Hong SW, Isono M, Chen S, et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol. 2001;158:1653–1663
   PubMed Web of Science ®Google Scholar
• Kanamaru Y, Nakao A, Tanaka Y, et al. Involvement of p300 in TGF-beta/Smad-pathway mediated alpha2(I) collagen expression in mouse mesangial cells. Nephron Exp Nephrol. 2003;95:e36–e42
   Google Scholar
• Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. 2002;13:1464–1472
   PubMed Web of Science ®Google Scholar
• Yamashita S. Ontogenic expression of estrogen receptor co-activators in the reproductive tract of female mice neonatally exposed to diethylstilbestrol. Reprod Toxicol. 2004;18:275–284
   PubMedGoogle Scholar
• Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: A novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology. 1997;31:400–407
   PubMed Web of Science ®Google Scholar
• Vyberg M, Nielsen S. Dextran polymer conjugate two step visualization system for immunohistochemistry. A comparison of EnVision+ with two three step avidinbiotin techniques. Appl Immunohistochem. 1998;61:3–10
   Google Scholar
• Sabattini E, Bisgaard K, Ascani S, et al. The EnVisionTM+ system: A new immunohistochemical method for diagnostics and research. Critical comparison with APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51:506–511
   PubMed Web of Science ®Google Scholar
• Kassimatis TI, Giannopoulou I, Koumoundourou D, Theodorakopoulou E, Varakis I, Nakopoulou L. Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: Correlation with renal injury. J Cell Mol Med. 2006;10(4):908–921
   Google Scholar
• Flanders K, Kim E, Roberts A. Immunohistochemical expression of Smads 1–6 in the 15-day gestation mouse embryo: Signaling by BMPs and TGF-betas. Dev Dyn. 2001;220:141–154
   Google Scholar
• Vrljicak P, Myburgh D, Ryan AK. Smad expression during kidney development. Am J Physiol Renal Physiol. 2004;286:F625–F633
   PubMedGoogle Scholar
• Goodman RH, Smolik S. CBP/p300 in cell growth, transformation and development. Genes Dev. 2000;14:1553–1577
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: Role in podocyte proliferation and maturation. Kidney Int. 2000;58(2):674–683
   Web of Science ®Google Scholar
• Srivastava T, Garola RE, Singh HK. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children. Kidney Int. 2006;70(3):529–533
   Google Scholar
• Hiromura K, Haseley LA, Zhang P, et al. Podocyte expression of the CDK inhibitor p57 during development and disease. Kidney Int. 2001;60(6):2235–2246
   PubMed Web of Science ®Google Scholar
• Nishimori S, Tanaka Y, Chiba T, et al. Smad-mediated transcription is regulated for transforming growth factor-beta 1-induced p57(kip2) proteolysis in osteoblastic cells. J Biol Chem. 2001;276:10700–10705
   PubMed Web of Science ®Google Scholar
• Urano T, Yashiroda H, Muraoka M, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. J Biol Chem. 1999;274:12197–12200
   PubMed Web of Science ®Google Scholar
• Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep. 2008;9:878–884
   Google Scholar
• Scandura JM, Boccuni P, Massaque J, et al. Transforming growth factor β-induced cell cycle arrest of hematopoietic cells requires p57kip2 up-regulation. Proc Natl Acad Sci. 2004;101:15231–15236
   PubMed Web of Science ®Google Scholar
• Chen Z, Li DQ, Tong L, et al. Targeted inhibition of p57 and p15 blocks transforming growth factor beta-inhibited proliferation of primary cultured human limbal epithelial cells. Mol Vis. 2006;23:983–994
   Google Scholar
• Sinuani I, Weissgarten J, Beberashvili I, et al. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: Effect of the immunomodulator AS101. Nephrol Dial Transplant. 2009;24(8):2328–2338
   Google Scholar
• Liu B, Preisig PA. TGF-β-mediated hypertrophy in rat renal epithelial cells involves inhibiting phosphorylation by preventing activation of cdk2/cyclin E kinase. Am J Physiol. 1999;277:186–194
   Google Scholar
• Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem Biol. 2010;17:471–482
   PubMedGoogle Scholar
• Iyer NG, Xian J, Chin SF, et al. p300 is required for orderly G1/S transition in human cancer cells. Oncogene. 2007;26:21–29
   PubMedGoogle Scholar
• Heemers HV, Debes JD, Tindall DJ. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv Exp Med Biol. 2008;617:535–540
   Google Scholar
• Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton). 2005;10:48–56
   PubMed Web of Science ®Google Scholar
• Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab. 1998;24:111–119
   PubMedGoogle Scholar
• Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity. 2007;26:579–591
   PubMed Web of Science ®Google Scholar
• Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25:455–471
   PubMed Web of Science ®Google Scholar
• Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther. 1997;4:553–1539
   PubMed Web of Science ®Google Scholar
• Subra JF, Cautain B, Xystrakis E, et al. The balance between CD45RChigh and CD45RClow CD4 T cells in rats is intrinsic to bone marrow-derived cells and is genetically controlled. J Immunol. 2001;166:2944–2952
   Google Scholar
• Fuss IJ, Boirivant M, Lacy B, Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol. 2002;168:900–908
   PubMed Web of Science ®Google Scholar
• Hansen G, McIntire JJ, Yeung VP, et al. CD4 T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 2000;105:61–70
   PubMed Web of Science ®Google Scholar
• Afrakhte M, Moren A, Jossan S, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun. 1998;249:505–511
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Iaria J, Sizeland AM. Smad7 differentially regulates transforming growth factor betamediated signaling pathways. J Biol Chem. 1999;274:32258–32264
   PubMedGoogle Scholar
• Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14:1535–1548
   PubMed Web of Science ®Google Scholar
• Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubblemediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol. 2005;166:761–771
   PubMed Web of Science ®Google Scholar
• Uchida K, Nitta K, Kobayashi H, et al. Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis. Mol Cell Biol Res Commun. 2000;4:98–105
   Google Scholar
• Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA. 2004;101:8687–8692
   Web of Science ®Google Scholar
• Chen H, Huang XR, Wang W, et al. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes. 2010;60:590–601
   Google Scholar
• Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: Role of Smad7. J Am Soc Nephrol. 2005;16:1371–1383
   PubMed Web of Science ®Google Scholar